1.   AutoImmune contracts with major pharmaceutical companies to deliver promising biotech products, then subcontracts out some of the research and development work to third parties.

2.   Biotech investing is difficult for most investors, because few of us understand the issues involved in assessing the potential worth of a biotech product.

3.   Both of these organisms could yield new biotech products and wind up in our foods and medicines.

4.   But those in the food industry say this was not a case of a biotech product being rushed to market without safety testing.

5.   Generic drugs would be cheaper and impact sales of brand-name biotech products.

6.   Intermune Pharmaceuticals and IntraBiotics Pharmaceuticals both have biotech products in late stage clinical trials, and Dietz thinks their success will signal biotech is back.

7.   One hundred thirteen biotech products are on the market, including some therapeutics classified as medical devices.

8.   Once biotech products hit the market and the benefits are known, consumer acceptance will be high, according to Glickman.

9.   The company has received regulatory approvals for several biotech products this year.

10.   The odds of pushing a biotech product through to regulatory approval are so long many companies flame out before they really get going.